BiotechTube

EVT 101 + EVT 101 + placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
28
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Human Volunteers

Conditions

Human Volunteers

Trial Timeline

Sep 1, 2007 → Dec 1, 2007

NCT ID
NCT00526968

About EVT 101 + EVT 101 + placebo

EVT 101 + EVT 101 + placebo is a phase 1 stage product being developed by Evotec for Human Volunteers. The current trial status is completed. This product is registered under clinical trial identifier NCT00526968. Target conditions include Human Volunteers.

Hype Score Breakdown

Clinical
10
Activity
5
Company
5
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT00526968Phase 1Completed

Competing Products

20 competing products in Human Volunteers

See all competitors
ProductCompanyStageHype Score
Influenza vaccine, split inactivatedComac MedicalPhase 1
25
CS-8958 + CS-8958 + oseltamivir phosphateDaiichi SankyoPhase 3
77
GSK1265744 30mg + Placebo + GSK1265744 5mgShionogiPhase 2
52
DolutegravirShionogiPhase 3
77
GSK1349572 + efavirenzShionogiPhase 2
52
Dolutegravir + Rlipivirine + GSK1265744ShionogiPhase 1
33
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg + Dolutegravir 50 mg + abacavir 600 mg/lamivudine 300 mgShionogiPhase 1
33
GSK1349572 (dolutegravir) + raltegravirShionogiPhase 3
77
Ortho-Cyclen + Dolutegravir + PlaceboShionogiPhase 1
33
GSK1349572 + Placebo + Iohexol Injection + Para-aminohippurate infusionShionogiPhase 1
33
dolutegravirShionogiPhase 3
77
Dolutegravir + Atripla + Abacavir/Lamivudine + Abacavir/Lamivudine Placebo + Dolutegravir placebo + Atripla placeboShionogiPhase 3
77
GSK1349572 + EfavirenzShionogiPhase 1
33
GSK1349572ShionogiPhase 1
33
GSK1349572 + PlaceboShionogiPhase 2
52
Dolutegravir + MethadoneShionogiPhase 1
33
GSK1349572 + Raltegravir + GSK1349572 Placebo + Raltegravir PlaceboShionogiPhase 3
77
GSK1349572 + Rifampin + RifabutinShionogiPhase 1
33
DTG + BCV + TVRShionogiPhase 1
33

Other Products from Evotec

EVT 302, 10 mg + placebo + Nicotine replacement therapy (NRT)Phase 2
47
EVT 201Phase 2
47
EVT 302 + Placebo + EVT 302 plus open label Nicotine replacement + Placebo plus open label Nicotine ReplacementPhase 2
47
EVT 201Phase 2
47
Monoclonal antibody JST-010 + PlaceboPhase 1
28